Outcomes of Patients With TP53-Mutated AML Receiving Allogeneic HSCT After First Induction or Salvage Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Leukemia
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Leukemia 2023 Feb 18;[EPub Ahead of Print], T Badar, E Atallah, R Shallis, AN Saliba, A Patel, JP Bewersdorf, J Grenet, M Stahl, A Duvall, M Burkart, N Palmisiano, D Bradshaw, M Kubiak, S Dinner, AD Goldberg, Y Abaza, GSG Murthy, V Kota, MR LitzowFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.